Akinsanya Karen
Officer at SDGR
- Sold, on record
- $7.6M
- Dollars the filings state
- Form 4 sales
- 11
- Latest Sep 17, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- SDGRSchrodinger, Inc.Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale SDGRUnusualJun 8, 2021 2021
Sold 16,721 shares at $75.37 ($1.3M)
Akinsanya Karen, Officer
Sold 100% of holdings ($1.3M position)0 shares left1.2x usual sizeFiling
- 2 Form 4 sale SDGRUnusualAug 16, 2021 +69 days
Sold 37,738 shares at $57.74 ($2.2M)
Akinsanya Karen, Officer
Sold 100% of holdings ($2.2M position)0 shares left2.5x usual sizeFiling
- 3 Form 4 sale SDGRUnusualSep 15, 2021 +30 days
Sold 1,394 shares at $61.13 ($85k)
Akinsanya Karen, Officer
Sold 100% of holdings ($85k position)0 shares left0.1x usual sizeFiling
- 4 Form 4 sale SDGRUnusualOct 15, 2021 +30 days
Sold 1,393 shares at $55.75 ($78k)
Akinsanya Karen, Officer
Sold 100% of holdings ($78k position)0 shares left0.1x usual sizeFiling
- 5 Form 4 sale SDGRRoutineApr 14, 2025 +1277 days
Sold 16,723 shares at $25.09 ($420k)
Akinsanya Karen, President of R&D, Therapeutics
10b5-1 planSold 51.7% of holdings ($812k position)15,625 shares leftFirst sale on recordFiling
- 6 Form 4 sale SDGRRoutineMar 2, 2026 +322 days
Sold 2,206 shares at $11.99 ($26k)
Akinsanya Karen, Officer
10b5-1 planSold 3% of holdings ($882k position)71,322 shares leftFiling
- 7 Form 4 sale SDGRRoutineMar 5, 2026 +3 days
Sold 1,366 shares at $12.90 ($18k)
Akinsanya Karen, Officer
10b5-1 planSold 1.9% of holdings ($920k position)69,956 shares leftFiling
- 8 Form 4 sale SDGRUnusualSep 17, 2026 +196 days
Sold 31,599 shares at $29.37 ($928k)
Akinsanya Karen, Officer
10b5-1 planSold 31.1% of holdings ($3M position)69,956 shares left14.3x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (11)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Sep 21, 2026 | SDGR | Officer | Form 4 sale | 31,599 | $928k | 31.1% | Unusual | SEC |
| Mar 5, 2026 | Mar 6, 2026 | SDGR | Officer | Form 4 sale | 1,366 | $18k | 1.9% | Routine | SEC |
| Mar 2, 2026 | Mar 3, 2026 | SDGR | Officer | Form 4 sale | 2,206 | $26k | 3.0% | Routine | SEC |
| Apr 14, 2025 | Apr 15, 2025 | SDGR | President of R&D, Therapeutics | Form 4 sale | 16,723 | $420k | 51.7% | Routine | SEC |
| Oct 15, 2021 | Oct 19, 2021 | SDGR | Officer | Form 4 sale | 1,393 | $78k | 100.0% | Unusual | SEC |
| Sep 15, 2021 | Sep 16, 2021 | SDGR | Officer | Form 4 sale | 1,394 | $85k | 100.0% | Unusual | SEC |
| Aug 16, 2021 | Aug 17, 2021 | SDGR | Officer | Form 4 sale | 37,738 | $2.2M | 100.0% | Unusual | SEC |
| Jun 8, 2021 | Jun 9, 2021 | SDGR | Officer | Form 4 sale | 16,721 | $1.3M | 100.0% | Unusual | SEC |
| Dec 18, 2020 | Dec 22, 2020 | SDGR | Officer | Form 4 sale | 13,377 | $1.1M | 100.0% | Unusual | SEC |
| Aug 17, 2020 | Aug 19, 2020 | SDGR | Officer | Form 4 sale | 3,344 | $228k | 100.0% | Unusual | SEC |
| Aug 12, 2020 | Aug 14, 2020 | SDGR | Officer | Form 4 sale | 20,065 | $1.4M | 100.0% | Unusual | SEC |